Matinas BioPharma Takes Equity Stake in Pro Soccer Team, The Can Kickers

Matinas BioPharma, a junior pharmaceutical company known for its lipid nano-crystal delivery platform, has made a surprising move by taking an equity stake in The Can Kickers, a professional soccer team.

The Can Kickers, who have been struggling in the league for years, are excited about the partnership with Matinas BioPharma. "We're thrilled to have Matinas on board as a partner," said team captain and star player, John "The Can Opener" Smith. "With their expertise in the medical field, we're hoping they can help us kick our injuries to the curb."

Matinas BioPharma Acting CEO, Theresa Matkovits, also seemed excited about the partnership. "We've always been passionate about sports and the health benefits it brings," said Dr. Matkovits. "At Matinas BioPharma, we believe that kicking the can down the road is not just a strategy, but one of our core values, so this business combination makes total sense.”

The Can Kickers are already seeing improvements on the field thanks to Matinas BioPharma's involvement. "We used to have a lot of trouble with cramps and strains," said team defender, Michael "The Can Crusher" Johnson. "But since Matinas came on board, we haven't had a single reported injury. It's like nobody is acknowledging anything and just ignoring their problems and hoping they’ll go away.”

"When faced with a problem, Matinas BioPharma's first reaction is not to solve it, it’s to kick the can down the road,” said investor Jazmyn Williams. “So, I can totally see why they invested in this soccer team. This thing with BioNTech is taking forever, and so is finding a partner for their oral fungal thingy. Everyone is saying how bad they are at closing deals, so why not change the subject?”

We spoke to Nobel prize-winning economist, Richard Thaler, who had this to say

“As an economist, I can't help but scratch my head at the recent news of Matinas BioPharma, a biotech company, investing in a professional sports team. On the surface, it seems like an odd move for a company that specializes in developing a cutting-edge drug delivery system. But, upon further analysis, there might be some logic behind the decision.

You see, Matinas BioPharma, like many other biotech companies, is facing a growing problem in the industry: skyrocketing R&D costs and a lack of access to the capital markets. As the race for new and innovative treatments intensifies, companies are forced to invest more money into research and development. This means that the return on investment for these companies is becoming increasingly uncertain.

But, by investing in a sports team, Matinas BioPharma is able to diversify their portfolio and spread out their risks. Not only that, but sports teams have a built-in fan base that can be leveraged for marketing and advertising, which Matinas obviously sucks at. They don’t even have a social media manager to take advantage of coincidences like the opening scene in that new zombie show, The Last of Us. The entire cold open of the show talks about the dangers of fungal infections. Matinas is working on the holy grail of antifungals, an oral version of amphotericin B. I mean, sure, anything they post on Twitter would be tongue-in-cheek, but come on. A company this small with only one year of cash left should be attracting attention at all costs. Increasing the visibility of Matinas BioPharma's products can lead to increased investment, and ultimately increased revenue.

Lastly, Investing in a sports team allows Matinas BioPharma to tap into the emotional connection that fans have with their teams. By aligning themselves with a beloved team like The Can Kickers, Matinas BioPharma can create a positive association in the minds of consumers. This can help to build brand loyalty and trust, which can be invaluable for a company in the biotech industry. All in all, I’d say good move by the acting CEO, but now they should really focus on tracking down the old CEO and figuring out what happened there. Although I did hear a rumor that Jerry Jabbour fled to Russia.”

While Matinas BioPharma's investment in The Can Kickers may seem like an unusual move for a biotech company, the partnership could potentially bring benefits for both parties. The Can Kickers could benefit from Matinas BioPharma's expertise in the medical field, while Matinas BioPharma could gain visibility and tap into the emotional connection that fans have with their teams. Thanks for reading and don’t forget to follow us on Twitter.